

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-102345-PIP01-26

Scope of the Application

Active Substance(s)

precemtabart tocentecan

Condition(s)

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms).

Pharmaceutical Form(s)

Powder for concentrate for solution for infusion

Route(s) of Administration

Intravenous use

Name / Corporate name of the PIP applicant

Merck Serono Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Serono Limited submitted to the licensing authority on 06/03/2026 18:08 GMT an application for a Waiver

The procedure started on 23/03/2026 21:38 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-102345-PIP01-26

Of 09/07/2026 08:38 BST

On the adopted decision for precentabart tocentecan (MHRA-102345-PIP01-26) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Waiver for precentabart tocentecan, Powder for concentrate for solution for infusion , Intravenous use .

This decision is addressed to Merck Serono Limited, 5 New Square, Bedfont Lakes Business Park, Feltham, London, UNITED KINGDOM, TW14 8HA

ANNEX I

1. Waiver

1.1 Condition:

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Powder for concentrate for solution for infusion Route(s) of administration: Intravenous use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not applicable

2.2 Indication(s) targeted by the PIP:

Not applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not applicable

2.4 Pharmaceutical Form(s):

Not applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures		
Non-Clinical Studies		
Clinical Studies		
Extrapolation, Modeling & Simulation Studies		
Other Studies		
Other Measures		

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	